SITC is pleased to announce a new educational offering for the society’s clinical practice guidelines – SITC’s Cancer Immunotherapy ...
SITC’s Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about ...
The SITC Multiple Myeloma Expert Panel has updated the guidelines content and recommendations based on the November 30, 2021 FDA approval ...
NOW AVAILABLEThe SITC Clinical Practice Guidelines (CPG) Mobile App is the first and only tool of its kind, offering direct, easy, portable access to SITC’s CPGs via phone or tablet. Highlighting key information from SITC’s published guidelines, the SITC CPG Mobile App features evidence- and expert consensus-based recommendations on important aspects of immunotherapy treatment as well as interactive tools and companion educational resources. Busy clinicians will find the SITC CPG Mobile App as the go-to resource on when and how to use immunotherapy to help improve outcomes for patients with cancer. Download the free app from the Apple Store or Google Play.
Click on the tiles below to bring you to the Guideline pages.
About the Guidelines
The SITC Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer.
These CPGs offer a vital resource for the practicing oncology community. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure a fair, transparent and balanced process for creating the CPGs. Each CPG expert panel is comprised of a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States.
The guidelines are reviewed on an ongoing basis to account for newly available clinical trial data and FDA approvals.
Cancer Immunotherapy Guidelines Oversight Committee
The Cancer Immunotherapy Guidelines Oversight Committee oversees the development of new clinical practice guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse events.
The committee determines the policies and protocols for the general guideline development process as well as the standards the expert panels must meet to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making leading to optimal patient care.
The committee also provides strategic insights into the existing dissemination efforts such as the post-publication webinars, pocket guides and mobile app development as well as envision and inform new dissemination tactics.
For questions regarding the SITC CPGs, please contact a member of the Scientific Publications Department at firstname.lastname@example.org.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com